IN2014CN03493A - - Google Patents

Download PDF

Info

Publication number
IN2014CN03493A
IN2014CN03493A IN3493CHN2014A IN2014CN03493A IN 2014CN03493 A IN2014CN03493 A IN 2014CN03493A IN 3493CHN2014 A IN3493CHN2014 A IN 3493CHN2014A IN 2014CN03493 A IN2014CN03493 A IN 2014CN03493A
Authority
IN
India
Prior art keywords
heterocyclic group
divalent heterocyclic
substituted
ring
cycloalkylene
Prior art date
Application number
Other languages
English (en)
Inventor
Yoshihito Tanaka
Shuzo Takeda
Hidemitsu Higashi
Mamoru Matsuura
Fujio Kobayashi
Maiko Hamada
Minoru Tanaka
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of IN2014CN03493A publication Critical patent/IN2014CN03493A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
IN3493CHN2014 2004-09-08 2005-09-08 IN2014CN03493A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004261655 2004-09-08
PCT/JP2005/017002 WO2006028284A1 (fr) 2004-09-08 2005-09-08 Dérivé de morpholine

Publications (1)

Publication Number Publication Date
IN2014CN03493A true IN2014CN03493A (fr) 2015-07-03

Family

ID=36036551

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3493CHN2014 IN2014CN03493A (fr) 2004-09-08 2005-09-08

Country Status (13)

Country Link
US (1) US7935700B2 (fr)
EP (1) EP1801108B9 (fr)
JP (1) JP4970946B2 (fr)
KR (1) KR101011848B1 (fr)
CN (1) CN101014580B (fr)
CA (1) CA2579207C (fr)
DK (1) DK1801108T3 (fr)
ES (1) ES2396419T3 (fr)
IN (1) IN2014CN03493A (fr)
PL (1) PL1801108T3 (fr)
PT (1) PT1801108E (fr)
TW (1) TW200619212A (fr)
WO (1) WO2006028284A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006082030A1 (fr) * 2005-02-04 2006-08-10 Ctg Pharma S.R.L. Nouveaux derives antipaludiques de la 4-aminoquinoline
KR101386494B1 (ko) 2005-05-10 2014-04-24 인사이트 코포레이션 인돌아민 2,3-디옥시게나제의 조절제 및 이의 사용방법
JP5294874B2 (ja) 2005-12-20 2013-09-18 インサイト・コーポレイション インドールアミン2,3−ジオキシゲナーゼのモジュレーターとしてのn−ヒドロキシアミジノヘテロ環
EP2042499B1 (fr) * 2006-07-11 2018-06-27 Mitsubishi Tanabe Pharma Corporation Sel d'un composé de morpholine
WO2008036642A2 (fr) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinohétérocycles en tant que modulateurs d'indoléamine 2,3-dioxygénase
CL2007002650A1 (es) * 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
WO2008036652A2 (fr) * 2006-09-19 2008-03-27 Incyte Corporation Amidines servant de modulateurs d'indoléamine 2,3-dioxygénase
WO2008058178A1 (fr) * 2006-11-08 2008-05-15 Incyte Corporation N-hydroxyamidinohétérocycles utilisés comme modulateurs de l'indoleamine 2,3-dioxygénase
WO2008123582A1 (fr) 2007-04-04 2008-10-16 Kowa Company, Ltd. Composé de tétrahydroisoquinoline
KR101649548B1 (ko) 2008-07-08 2016-08-19 인사이트 홀딩스 코포레이션 인돌아민 2,3-디옥시게나아제의 억제제로서의 1,2,5-옥사디아졸
WO2015012332A1 (fr) * 2013-07-24 2015-01-29 田辺三菱製薬株式会社 Agent thérapeutique pour maladie ophtalmique
MX366874B (es) 2013-11-08 2019-07-29 Incyte Holdings Corp Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa.
WO2020203822A1 (fr) * 2019-03-29 2020-10-08 千寿製薬株式会社 Médicament combiné pour le traitement ou la prévention d'une maladie rétinienne associée à l'angiogenèse
EP4021898A1 (fr) * 2019-08-26 2022-07-06 Stichting VUmc Inhibition de la sécrétion mycobactérienne de type vii

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870074A (en) * 1986-04-30 1989-09-26 Dainippon Pharmaceutical Co., Ltd. Substituted benzamide derivatives, for enhancing gastrointestinal motility
JPS63264467A (ja) * 1986-04-30 1988-11-01 Dainippon Pharmaceut Co Ltd ベンズアミド誘導体
JPH03148276A (ja) * 1989-11-01 1991-06-25 Yoshitomi Pharmaceut Ind Ltd 光学活性なピリドンカルボン酸化合物
AU1208397A (en) 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
AU729415B2 (en) 1996-07-12 2001-02-01 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AU3633997A (en) 1996-07-29 1998-02-20 Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
WO1999055330A1 (fr) 1998-04-27 1999-11-04 Smithkline Beecham Corporation Antagonistes du recepteur ccr-3
CA2329777A1 (fr) 1998-04-27 1999-11-04 Dashyant Dhanak Antagonistes du recepteur ccr-3
BR9915735A (pt) 1998-11-20 2001-09-04 Hoffmann La Roche Antagonistas receptores de ccr-3 de piperidina
WO2000034278A1 (fr) 1998-12-04 2000-06-15 Toray Industries, Inc. Derives triazolo, et inhibiteurs de chimiokines contenant ces derives comme ingredient actif
WO2000053600A1 (fr) * 1999-03-11 2000-09-14 Banyu Pharmaceutical Co., Ltd. Derives piperidiniques
BR0009338A (pt) 1999-03-26 2001-12-26 Astrazeneca Ab Composto, processo para a preparação do mesmo,composição farmacêutica, processo para apreparação da mesma, uso de um composto, e,método de tratamento de uma doençainflamatória em um paciente sofrendo ou em riscode dita doença
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
AU2001280187A1 (en) 2000-08-28 2002-03-13 Toray Industries, Inc. Cyclic amine derivatives
PL362984A1 (en) 2000-09-29 2004-11-15 Glaxo Group Limited Compounds useful in the treatment of inflammatory diseases
CN1678594A (zh) * 2000-09-29 2005-10-05 葛兰素集团有限公司 用于治疗炎性疾病的吗啉-乙酰胺衍生物
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
CA2445348A1 (fr) 2001-04-27 2002-11-07 Mitsubishi Pharma Corporation Nouveaux composes de benzylpiperidine
GB0207445D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207443D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0207436D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0208158D0 (en) 2002-03-28 2002-05-22 Glaxo Group Ltd Novel compounds
TW200400035A (en) 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
GB0207439D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
GB0212355D0 (en) 2002-05-29 2002-07-10 Glaxo Group Ltd Novel compounds
GB0212357D0 (en) 2002-05-29 2002-07-10 Glaxo Group Ltd Novel compounds
PL375263A1 (en) * 2002-07-02 2005-11-28 F.Hoffmann-La Roche Ag 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists

Also Published As

Publication number Publication date
JP4970946B2 (ja) 2012-07-11
WO2006028284A1 (fr) 2006-03-16
TWI367209B (fr) 2012-07-01
ES2396419T3 (es) 2013-02-21
DK1801108T3 (da) 2013-02-18
PL1801108T3 (pl) 2013-04-30
EP1801108A1 (fr) 2007-06-27
US7935700B2 (en) 2011-05-03
CA2579207C (fr) 2011-10-18
TW200619212A (en) 2006-06-16
EP1801108B1 (fr) 2012-11-14
JPWO2006028284A1 (ja) 2008-05-08
KR101011848B1 (ko) 2011-02-01
EP1801108B9 (fr) 2013-11-20
US20070265257A1 (en) 2007-11-15
KR20070099528A (ko) 2007-10-09
CN101014580B (zh) 2011-05-04
CA2579207A1 (fr) 2006-03-16
CN101014580A (zh) 2007-08-08
EP1801108A4 (fr) 2010-10-13
PT1801108E (pt) 2012-12-03

Similar Documents

Publication Publication Date Title
IN2014CN03493A (fr)
MX2009012283A (es) Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1.
CA2316902A1 (fr) Derives alpha-aminoamides utiles en tant qu'agents analgesiques
JP2006521359A5 (fr)
MY145408A (en) Dihydropyrazolopyrimidinone derivatives
EP1798226A4 (fr) Derive de traizol
IL189069A0 (en) Piperidine and piperazine derivatives as p2x3 antagonists
TW200605883A (en) Condensed heterocycle derivative having HCV inhibitory activity
SG160195A1 (en) N-phenyl-2-pyrimidine-amine derivatives
TW200745034A (en) New compounds
NO20052993L (no) 4,5-diaryltiazolderivater som CB-1 ligander.
EP1533292A4 (fr) Compose dibenzylamine et utilisation medicinale de ce compose
JO2791B1 (en) Acid secretion inhibitor
UA83243C2 (ru) Соединения, которые ингибируют натриезависимый переносчик глюкозы
NZ590355A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
EP1642880A4 (fr) Inhibiteur de proteines de la famille hsp90
AU2003254852A8 (en) Fused heterocyclic compounds as peptidase inhibitors
TW200726470A (en) 6,7-unsaturated-7-carbamoylmorphinan derivatives
DE69505968D1 (de) Azolidindion-derivate und ihre anwendung als antihyperglykämika
WO2008136444A1 (fr) Dérivé hétérocyclique fusionné
WO2004017977A3 (fr) Derives de morpholine
TW200503712A (en) (2-carboxamido)(3-amino)thiophene compounds
WO2008153042A1 (fr) Agent antitumoral
TW200510361A (en) Process of preparating 3-acylaminobenzofuran-2-carboxylic acid derivatives
WO2005061475A3 (fr) Derives d'ornithine utilises comme agonistes ou antagonistes de la prostaglandine e2